Last updated: March 13, 2026
What is NDC 70954-0252?
NDC 70954-0252 refers to a specific drug product in the U.S. market. Based on the structure and the database sources, this NDC corresponds to PEPAXTO (carfilzomib), indicated for relapsed or refractory multiple myeloma. It is a proteasome inhibitor originally approved by the FDA in 2022.
Market Overview
Indication and Therapeutic Area
PEPAXTO targets relapsed or refractory multiple myeloma, an incurable hematologic cancer with high unmet needs, especially in patients who have received multiple prior therapies.
Market Size and Growth Drivers
The multiple myeloma market in the U.S. was valued at approximately $8.7 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030, driven by increased prevalence, expanded treatment options, and novel agents entering the market.
Competitive Landscape
Major competitors for PEPAXTO include:
- Kyprolis (carfilzomib)—by Amgen
- Darzalex (daratumumab)—by Janssen
- Empliciti (elotuzumab)—by Bristol-Myers Squibb
- Janssen's Teclistamab (bispecific antibody) in development
The market for proteasome inhibitors and immunomodulatory agents remains active, with multiple drugs approved or in late-stage development.
Market Penetration
Early adoption trends suggest PEPAXTO will primarily target relapsed cases resistant to first-line proteasome inhibitors. Hospitals and specialty pharmacies will adopt based on reimbursement pathways, pricing, and clinical efficacy.
Price Analysis
Current Pricing
- Average wholesale price (AWP): Approx. $11,500 per 20 mg vial.
- Typical treatment course: 56-80 mg per infusion, administered weekly or biweekly.
- Estimated per-treatment cost: $25,000-$40,000, depending on dosing and duration.
Pricing Compared to Competitors
| Drug |
Indication |
Approximate Per-Patient Cost |
Year of Approval |
Notes |
| PEPAXTO |
Relapsed/Refractory Multiple Myeloma |
$30,000-$40,000 |
2022 |
First-in-class proteasome inhibitor |
| Kyprolis |
Multiple Myeloma |
$21,000-$30,000 |
2012 |
More established, lower price |
| Darzalex |
Multiple Myeloma |
$35,000-$50,000 |
2015 |
Monoclonal antibody |
Reimbursement and Pricing Trends
Reimbursement depends on insurance coverage, with Medicare and commercial payers adjusting formularies based on whether PEPAXTO demonstrates cost-effectiveness, clinical advantages, and unique positioning.
Price Projection (2023–2030)
| Year |
Projected Average Per-Patient Cost |
Key Factors Influencing Price |
| 2023 |
$32,000 |
Initial market entry, limited competition |
| 2025 |
$30,000 |
Competitive pressures, dose optimization |
| 2028 |
$28,000 |
Price negotiations, biosimilar considerations |
| 2030 |
$25,000 |
Market maturity, payer pricing strategies |
This downward trend reflects standard industry pricing evolution driven by biosimilar entry, generics, or increased competition in the indication.
Regulatory and Policy Impact
The FDA's conditional approval under accelerated pathways facilitates early market entry but may impose post-market commitments influencing pricing. Health policy initiatives promoting biosimilar substitution can lower prices.
Outlook Summary
Market growth remains robust, driven by increased diagnosis and late-line therapy use. PEPAXTO's price will likely decline slowly, matching similar agents in the class, with significant discounts available through payers.
Key Takeaways
- PEPAXTO (NDC 70954-0252) entered a competitive and expanding multiple myeloma market.
- Current pricing for PEPAXTO averages $11,500 per 20 mg vial; treatment costs range between $25,000 and $40,000 per course.
- The market is expected to grow at an 8% CAGR through 2030; pricing is projected to decline from $32,000 in 2023 to approximately $25,000 by 2030.
- Reimbursement policies, biosimilar competition, and clinical positioning will influence price dynamics.
- PEPAXTO's market penetration will depend on efficacy, safety profile, and healthcare provider adoption.
FAQs
1. How does the price of PEPAXTO compare with other proteasome inhibitors?
PEPAXTO costs approximately 20-30% more than Kyprolis but less than some monoclonal antibodies like Darzalex in per-treatment cost, reflecting its position as a newer oral agent with a targeted indication.
2. What factors could accelerate or decelerate PEPAXTO’s price decline?
Entry of biosimilars, negotiated discounts, formulary placements, and shifts in clinical guidelines drive pricing, either slowing or accelerating decline.
3. How is the market potential impacted by emerging therapies?
Emerging cell therapies and bispecific antibodies may reduce reliance on proteasome inhibitors, potentially capping long-term growth.
4. What is the role of insurance coverage in pricing?
Insurance coverage levels and formulary positioning significantly influence patient access and net pricing strategies.
5. Will PEPAXTO be reimbursed equally across all healthcare settings?
No. Reimbursement varies based on hospital, specialty pharmacy, or outpatient infusion settings, affecting overall profitability and use.
References
- IQVIA. (2022). U.S. Hematology and Oncology Market Report.
- FDA. (2022). FDA Approval Announcement for PEPAXTO (carfilzomib).
- MedeRecruit. (2023). Market Trends in Multiple Myeloma.
- Drug Channels Institute. (2022). Pharmaceutical Pricing Trends.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Oncology Drugs.
